| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f229d94e1dec4a1b86e1e34c282480c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48723 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2013-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c23bc20b4d3751e3a3d7ab355d7b4ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0230eaa36b86d9f747aa42acf57af32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5628867d2c4845484342347faad7ff7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3957797337fe3ef53df3c6b9c7e0b1d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8f5b761589372f6b12b12f7507e3b0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c136d605a2c760684ef52a9573d4ea9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9336069629683262b9a2d6118f41a06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2f44ca2a169beca6babf076d8d5ed79 |
| publicationDate |
2015-10-22^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015297674-A1 |
| titleOfInvention |
Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or disease |
| abstract |
A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9414967-B2 |
| priorityDate |
2012-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |